The Global Kidney Cancer Diagnostics and Therapeutics Market was worth $3.47 billion in 2018 and estimated to be growing at a CAGR of 5.64%, to reach $4.57 billion by 2023. Though there has been considerable development in science and technology to tackle cancer, it continues to threaten lives across the world.
Kidney cancer is one of the frequent urologic tumours accounting for around 3% of all human cancers. The frequency rate of renal cell carcinoma has increased gradually in the recent decades.
The growth of the Global Kidney Cancer Diagnostics and Therapeutics Market is mainly driven by factors such as rising aging population, Changes in lifestyle such as increased intake of alcohol and disproportionate smoking, and government policies to provide better care for kidney Cancer. However, high costs of screening tests, minimal success rate in clinical trials, and poor availability of proper cancer care in the emerging regions are restraining the growth of the market.
The Global Kidney Cancer Diagnostics and Therapeutics market is segmented based on Type and Tests. The market for Kidney Cancer Diagnostics and Therapeutics, on the basis of Type it is segmented into Transitional Cell Cancer, Renal cell carcinoma, Renal sarcoma, and Others. On the basis of Tests, the global Kidney Cancer Diagnostics and Therapeutics market is segmented into Biopsy, CT Scan, Cystoscopy, Intravenous pyelogram, Kidney Ultrasound. Biopsy and CT Scan lead the tests segment in the Global Kidney Cancer Diagnostics and Therapeutics market accounting for more than 50% of the market.
The market has also been geographically segmented into North America, Europe, Asia-Pacific and the Rest of the World. North America accounted for the largest share in the global Kidney Cancer Diagnostics and Therapeutics market followed by Asia-Pacific and Europe. The frequency of this disease was higher in developed countries than in developing nations due to lifestyle factors. However, The Asia-Pacific region is anticipated to increase at the highest CAGR during the forecast period due to factors such as low expense of drug production and the mounting patient base suffering from these diseases.
The major companies dominating the Kidney Cancer Diagnostics and Therapeutics market are GlaxoSmithKline, Bayer, Pfizer, Sanofi S.A, Hoffmann La Roche, Novartis, Abbott Laboratories.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Type
5.1.1 Transitional Cell Cancer
5.1.2 Renal cell carcinoma
5.1.3 Renal sarcoma
5.1.4 Other Cancers
5.2 By Tests
5.2.1 Biopsy
5.2.2 CT Scan
5.2.3 Cystoscopy
5.2.4 Intravenous pyelogram
5.2.5 Kidney Ultrasound
6. Geographical Analysis
6.1 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.2 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.3 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 South Korea
6.3.6 Australia
6.4 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Argentina
6.4.4 Mexico
6.4.5 Rest of Latin America
6.5 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle-East
6.5.3 Africa
7. Pipeline Product Analysis
7.1 Overview
7.2 Pipeline Development Landscape
7.3 Molecular Targets in the Pipeline
7.4 Clinical Trials
7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target.
8.Strategic Analysis
8.1 PESTLE analysis
8.1.1 Political
8.1.2 Economic
8.1.3 Social
8.1.4 Technological
8.1.5 Legal
8.1.6 Environmental
8.2 Porter’s Five analysis
8.2.1 Bargaining Power of Suppliers
8.2.2 Bargaining Power of Consumers
8.2.3 Threat of New Entrants
8.2.4 Threat of Substitute Products and Services
8.2.5 Competitive Rivalry within the Industry
9.Market Leaders' Analysis
9.1 GlaxoSmithKline
9.1.1 Overview
9.1.2 Product Analysis
9.1.3 Strategic Evaluation and Operations
9.1.4 Financial analysis
9.1.5 Legal issues
9.1.6 Recent Developments
9.1.7 SWOT analysis
9.1.8 Analyst View
9.2 Bayer
9.3 Pfizer
9.4 Sanofi S.A
9.5 Hoffmann La Roche
9.6 Novartis
9.7 Abbott Laboratories
10.Competitive Landscape
10.1 Market share analysis
10.2 Merger and Acquisition Analysis
10.3 Agreements, collaborations and Joint Ventures
10.4 New Product Launches
11.Expert Opinions
11.1 Market Outlook
11.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
